Your Semaglutide Timeline: How Long It Takes for Semaglutide to Work for Weight Loss

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide starts acting pharmacologically within days but takes months to produce the weight change people are asking about. The Ozempic prescribing information reports that maximum concentration is reached 1 to 3 days after a dose and that steady-state exposure is achieved after 4 to 5 weeks of once-weekly administration. The weight endpoints, by contrast, were measured at 68 and 72 weeks. That gap between when the drug is fully on board and when the outcome is read is the single most useful thing to understand about this timeline.

Weeks 1 to 5: Pharmacokinetics, Not Results

Semaglutide is absorbed with an absolute bioavailability of 89% following subcutaneous administration, and maximum concentration is reached 1 to 3 days post dose. Because the elimination half-life is approximately one week, concentrations accumulate across successive weekly doses until steady state is reached after 4 to 5 weeks.

Labeled starting dosages are deliberately below the maintenance range. The Ozempic label starts at 0.25 mg once weekly with an increase to 0.5 mg after four weeks; the Wegovy label initiates at 0.25 mg once weekly for four weeks and then follows a titration schedule every four weeks toward a maintenance dosage. Early low dosages exist to manage tolerability, not to deliver effect.

What people commonly notice in this window is appetite and gastrointestinal change. That is a real pharmacodynamic effect. It is not the same thing as the weight outcome and does not predict it.

Months 2 to 6: Where the Curve Is Steepest

Across the semaglutide weight-management programme, the fastest rate of weight change occurs through the first several months, during and shortly after titration to maintenance. This is the phase where the medication is at full exposure and the counter-regulatory response has not yet fully engaged.

It is also the phase in which the adverse-event burden is most visible. Gastrointestinal reactions — nausea, vomiting, diarrhoea, abdominal pain and constipation — are the most commonly reported reactions across these labels, and in the tirzepatide programme they occurred primarily during dose escalation. The same pattern holds here.

Months 9 to 17: The Plateau and the Endpoint

The pivotal trials read out at 68 weeks for the 2.4 mg programme and 72 weeks for the higher dosage programme. Those durations exist because that is roughly how long the weight curve takes to flatten.

Wegovy Study 2, a 68-week trial enrolling 1,961 patients with obesity or with overweight plus at least one weight-related comorbid condition and excluding type 2 diabetes, reported a mean body weight change of −14.9% versus −2.4% with placebo. Study 4, which paired the medication with intensive lifestyle therapy over the same period, reported −16% versus −5.7%.

Study 3, in 807 patients with type 2 diabetes and body mass index of at least 27 kg/m², reported −9.6% versus −3.4%. If you have type 2 diabetes, the diabetes-population figure is the more relevant benchmark.

Why Your Timeline Will Not Match the Trial Timeline

Every published number is a group mean. Trial reports also publish the proportions achieving 5%, 10% and 15% loss precisely because the spread around that mean is wide, and individual trajectories inside a single arm differ substantially.

Three factors move an individual timeline more than anything else: whether the diet and activity component of the labeled regimen is genuinely in place, whether dosing is continuous, and whether coexisting conditions such as type 2 diabetes are present. Trial participants received instruction for an approximately 500 kcal per day deficit and counselling toward at least 150 minutes of physical activity per week.

Discontinuation is common outside trials. Recent reviews report that a substantial share of GLP-1 receptor agonist users stop within a year of initiation, and interrupted exposure produces interrupted results.

What Is Worth Measuring Along the Way

Daily weight readings are dominated by fluid and glycogen shifts and are close to useless as a progress signal. A three-month trend line is far more informative than a week-to-week one.

Weight is also not the only measured outcome. In SURMOUNT-5, waist circumference fell −13.0 cm over 72 weeks in the semaglutide arm alongside a −13.7% weight change, and the pivotal programmes also tracked blood pressure, lipids and glycemic parameters. Those measures matter clinically and often move on their own schedule.

Planning Beyond the Endpoint

A timeline that stops at the plateau is incomplete. Randomised withdrawal trials in this class consistently show substantial weight regain after discontinuation, with a 2026 review in EClinicalMedicine reporting that roughly two-thirds of lost weight is typically regained within a year of stopping, together with reversal of some cardiometabolic improvements.

The labels are written accordingly: the Wegovy weight indication is to reduce excess body weight and maintain weight reduction long term. Discuss the maintenance phase with your prescriber at the start, not when you reach it.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How soon does semaglutide start working?

Pharmacologically, quickly. Maximum concentration is reached 1 to 3 days after a dose and steady-state exposure is achieved after 4 to 5 weeks of once-weekly administration, with an elimination half-life of approximately one week. The weight-management endpoints in the pivotal trials, however, were measured at 68 weeks, so early appetite change is not the same thing as the outcome.

When should I expect to see weight change?

The steepest portion of the weight curve in the pivotal trials falls in the first several months, during and shortly after titration to a maintenance dosage, with the curve flattening later in the 68-week to 72-week trial window. Individual trajectories disperse widely around the group mean, which is why trials also report the proportions reaching 5%, 10% and 15% loss.

Why did the trials run 68 or 72 weeks?

Because that is approximately how long the weight curve takes to plateau in this class. Wegovy Study 2 ran 68 weeks and reported mean change of minus 14.9% versus minus 2.4% with placebo. The higher-dosage programme ran 72 weeks. Shorter trials would have measured the medication mid-trajectory and produced numbers that understate the eventual plateau.

Does having type 2 diabetes change the timeline?

It changes the expected magnitude more than the shape. Wegovy Study 3, in 807 patients with type 2 diabetes and body mass index of at least 27 kg/m2, reported mean weight change of minus 9.6% versus minus 3.4% with placebo at 68 weeks, smaller than the minus 14.9% seen in the diabetes-free population. That smaller effect in diabetes is consistent across this drug class.

What if nothing is happening after two months?

That is a conversation for your prescriber rather than a reason to change anything on your own. The labels direct that treatment response and tolerability be considered when selecting a maintenance dosage, which presupposes clinical review. Verify first that the dosing has been continuous and that the diet and activity component of the labeled regimen is actually in place.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.